# CorMedix Inc. (CRMD) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $8.43, market value $657 million.

## Valuation
- **P/E (trailing): 3.9×** (5-yr avg 5.7×, 3-yr avg 5.7×). CorMedix Inc. trades at 3.9× trailing earnings, well below its own five-year average of 5.7×: cheap by its own standards. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 24.1×, higher than trailing, so analysts expect earnings to fall.
- **PEG: 0.03**. A PEG of 0.03 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 1.4×**. Each dollar of revenue is priced at 1.4×.
- **Price / book: 1.4×**. The shares trade at 1.4× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 38.1%** (5-yr avg -8.0%). Free cash flow equals 38.1% of the market value, above its five-year average of -8.0%, so the shares are cheaper on cash than they have usually been. Above 5% is generally attractive.
- **Earnings yield: 25.9%**. The inverse of the P/E: 25.9% of the price is earned each year.

## Profitability
- **Gross margin: 82.8%**. CorMedix Inc. keeps 82.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 47.0%**. 47.0% of revenue is left after running the business, an exceptional level.
- **Net margin: 52.3%**. 52.3% of each dollar of sales reaches the bottom line.
- **Return on equity: 40.2%**. 40.2% on shareholders' equity is excellent if it is not driven by leverage; sustained above 20% usually signals a competitive advantage.
- **Return on assets: 22.7%**. Each dollar of assets produces 22.7% of profit.

## Growth
- **Revenue growth (1 yr): 617.0%** (3-yr 1582.8%/yr, 5-yr 319.7%/yr). Revenue grew 617.0% over the last year, against 319.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 780.0%**. Earnings per share rose 780.0%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Current ratio: 2.11** (quick 2.11). Current assets cover the next year's liabilities 2.11 times.
- **Altman Z-score: 2.88**. A Z-score of 2.88 is in the grey zone; not distressed, not clearly safe.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. CorMedix Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover CorMedix Inc.; the consensus is buy, with an average price target of $15.40 (+83% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -34.1%** (YTD -27.5%, 3-mo 0.8%). The shares are down 34.1% over twelve months including dividends.
- **From 52-week high: -39.0%** (37.5% above the low). Trading 39% below its 52-week high, deep in a drawdown.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 56**. An RSI of 56 is neutral.
- **Beta (1 yr): 1.22** (volatility 63%). Beta of 1.22 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=CRMD · Page: https://foliofundamentals.com/stocks/crmd

Not investment advice.